Calypte sells Pepgen to focus on diagnostics:
This article was originally published in Clinica
Calypte Biomedical has sold its 29% stake in Pepgen, a privately-owned therapy company, developing new forms of interferon for multiple sclerosis and hepatitis C, for $500,000. Alameda, California-based Calypte said that the divestment was based on the company's financial needs and the strategic commitment to focusing its efforts on diagnostics.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.